DS
IMUC

DRW Securities’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

DRW Securities’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,000
Closed -$111K – 278
2013
Q4 		$111K Buy
+3,000
New +$284K ﹤0.01% 205

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DRW Securities's IMUC Position: Q1 2014 in Review

DRW Securities sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2014, closing a stake of 3,000 shares — an estimated $111K sold.

DRW Securities first reported a position in IMUC in Q4 2013 and held it in 1 quarter. The position peaked at $111K in Q4 2013. 36 funds tracked by Wall St. Rank hold IMUC as of Q1 2014.

  • DRW Securities reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2014 after selling out during the quarter.
  • DRW Securities sold 3,000 ImmunoCellular Therapeutics, Ltd. shares in Q1 2014, an estimated $111K.
  • DRW Securities first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2013 and held it in 1 quarter.
  • DRW Securities's ImmunoCellular Therapeutics, Ltd. position peaked at $111K in Q4 2013.
  • 36 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2014.

Based on DRW Securities's 13F filing for Q1 2014, filed 16 May 2014.